It was going to happen, and even though many of the top cannabis stocks are based in Canada and get coverage there, until recently, there has been little major Wall Street coverage in the United States. However, that is changing and changing fast, and needless to say, the marijuana industry now is sort of like the beginning of the dot-com era in the mid-1990s. With that in mind, it is entirely possible that some of the companies that are in the mix now could be long gone five or 10 years from now.
[in-text-ad]
Merrill Lynch has coverage on the industry, and when a major Wall Street firm like Merrill starts and maintains coverage, it pretty much legitimizes things for good. The analysts remain very positive on five cannabis companies, rating their stocks at Buy, and said they said this in a recent report:
Canada’s cannabis market is coming to life after a tepid start, and we expect strong growth to sustain ahead. Despite attractive trends, however, Wall Street expectations on an absolute basis seem aggressive based on current market size. Canada may need to add at least 400 stores in one year just to get close to expectations.
Aurora Cannabis
This company has made a string of acquisitions to grow the scale of its overall business and saw industry-leading sales in the first quarter. Aurora Cannabis Inc. (NYSE: ACB) produces and distributes medical cannabis products. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, from facility engineering and design to cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.
The company’s products consist of dried cannabis and cannabis oil, CanniMed vegan capsules and hemp products, as well as sells vaporizers, consumable vaporizer accessories and herb mills for using herbal cannabis products. It also operates CanvasRX, a network of cannabis counseling and outreach centers, and it provides cannabis analytical product testing services.
Merrill has a $10 price target on the shares, and no Wall Street consensus target was posted, even though other companies cover the stock. Shares were last seen trading at $7.54 apiece.
CannTrust
This could be an off-the-radar play for investors looking for a marijuana play with lower name recognition. CannTrust Holdings Inc. (NYSE: CTST) produces and distributes pharmaceutical-grade medical cannabis products in Canada. It sells dried cannabis and oil extractions to clients based on the medication documentation provided by health care practitioners. The company has a partnership with Gold Coast University Hospital.
CannTrust also focuses on developing nanotechnology to create new products in the medical, recreational, beauty, wellness and pet markets. In addition, the company recently completed a successful secondary offering, and management noted in late April that it expects to report strong first-quarter results.
The Merrill price target on the stock is $8. The stock ended last week trading at $4.94 per share.
24/7 Wall St.Canopy Growth
This is among the largest marijuana companies from a market capitalization basis. Canopy Growth Corp. (NYSE: CGC), with its subsidiaries, engages in growing, possession and sale of medical cannabis in Canada. Its products include dried flowers, oils and concentrates, softgel capsules and hemps. The company offers its products under the Tweed, Black Label, Spectrum Cannabis, DNA Genetics, Leafs by Snoop, Bedrocan Canada, CraftGrow and Foria brand names
The company also offers its products through Tweed Main Street, a single online platform that enables registered patients to purchase medicinal cannabis from various producers across various brands. The company was formerly known as Tweed Marijuana and changed its name to Canopy Growth in September 2015.
The Merrill analysts have put a $53 price target on the shares, which trading most recently at $40.16.
Cronus
A major international company took a large position in Cronus Group Inc. (NASDAQ: CRON) late in 2018. This is a global cannabis company founded in 2012 and based in Ontario, Canada, with a presence across five continents. Its principal activities are the production and sale of cannabis and cannabis-derived products in federally legal jurisdictions.
Back in December, Altria agreed to buy a 45% stake in the company for about $1.8 billion, a sign of the new world in which the tobacco company must compete. This strategic partnership provides Cronos with additional financial resources, product development and commercialization capabilities, as well as deep regulatory expertise, to better position the company to compete, scale and lead the rapidly growing global cannabis industry. The stake also gives Altria the option to increase to full ownership if it so chooses down the road.
The $19 Merrill price target compares with the most recent close at $15.29 a share.
24/7 Wall St.Hexo
This is another popular stock in the fast-expanding marijuana arena. Hexo Corp (NYSE: HEXO) is a diversified company, selling a portfolio of cannabis and related products. The company is based in Quebec, where it is a preferred supplier to the province’s provincial cannabis purchaser. The company also has national distribution, with plans to expand internationally.
Through its hub and spoke business strategy, Hexo partners with Fortune 500 companies, bringing its brand value, cannabinoid isolation technology, licensed infrastructure and regulatory expertise to established companies, leveraging their distribution networks and capacity. As one of the largest licensed cannabis companies in Canada, Hexo operates with 1.8 million square feet of facilities in Ontario and Quebec, and a foothold in Greece to establish a eurozone processing, production and distribution center. The company serves the Canadian adult-use and medical markets.
The analysts at Merrill have an $8 price target. The stock closed at $5.20 on Friday.
Other brokerage firms have started coverage on the marijuana industry, but Merrill is one of the biggest players on Wall Street to begin full-scale coverage. While legalization for recreational and medical use has sped up in recent years, to some investors there remains the taboo, given that marijuana is a drug that is still illegal in the United States on a federal basis.
With that in mind, the fact of the matter is we should see an increasing number of states legalizing its recreational use, as the consumer demand is there, as is the potential for huge tax windfalls. Illinois was the most recent of the 11 states to legalize recreational use and sales, starting on January 1 of 2020. There will be more to follow, as the issue is being discussed in numerous states.
Sponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
